Drug intelligence / Profile preview

Ozogamicin

Development stage: Unknown
Lead developer: Pfizer
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ozogamicin is a calicheamicin derivative used as a cytotoxic agent in antibody-drug conjugates (ADCs). It works by inducing double-strand DNA breaks, leading to cell cycle arrest and apoptosis in targeted cancer cells. Ozogamicin is linked to monoclonal antibodies targeting specific antigens on cancer cells, such as CD33 in Gemtuzumab ozogamicin and CD22 in Inotuzumab ozogamicin[1][4].

Other names: Ozogamicin (in the context of its use as a cytotoxin in ADCs)

Targets

DNA

Beyond the preview

Go deeper on Ozogamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ozogamicin.

Explore the full profile